Initial Opioid Prescriptions among U.S. Commercially Insured Patients, 2012–2017

Abstract

BACKGROUND The United States is undergoing a crippling opioid epidemic, spurred in part by overuse of prescription opioids by adults 25 to 64 years of age. Of concern are long-duration and high-dose initial prescriptions, which place the patients and their friends and relatives at heightened risk for long-term opioid use, misuse, overdose, and death. METHODS We estimated the incidence of initial opioid prescriptions in each month between July 2012 and December 2017 using administrative-claims data from across the United States (accessed through Blue Cross–Blue Shield [BCBS] Axis); monthly incidence was estimated as the percentage of enrollees who received an initial opioid prescription among those who had not used opioids (i.e., no opioid pre-scription or a diagnosis of opioid use disorder in the 6 months before a given month). We then estimated the percentage of enrollees initiating opioid therapy who received a long-duration or high-dose initial opioid prescription in each month during this period. We also calculated the number of providers who initiated opioid therapy in any patient who had not used opioids in each month and examined monthly trends in the duration and dose of initial opioid prescriptions in prescriber and patient subgroups. Our study sample included 63,817,512 enrollees who had not used opioids (mean, 15,897,673 per month). RESULTS The monthly incidence of initial opioid prescriptions among enrollees who had not used opioids declined by 54%, from 1.63% in July 2012 to 0.75% in December 2017. This decline was accompanied by a decreasing number of providers (from 114,043 in July 2012 to 80,462 in December 2017) who initiated opioid therapy in any patient who had not used opioids. Nonetheless, among the shrinking sub-group of physicians who initiated opioid therapy in such patients, high-risk prescribing (i.e., prescriptions for more than a 3-day supply or for a dose of 50 morphine milligram equivalents per day or higher) persisted at a monthly rate of 115,378 prescriptions per 15,897,673 enrollees who had not used opioids. CONCLUSIONS As the opioid crisis progressed between July 2012 and December 2017, many providers stopped initiating opioid therapy. Although the number of initial opioid prescriptions declined, a subgroup of providers continued to write high-risk initial opioid prescriptions. (Funded by the National Institute on Aging and a gift from Owen and Linda Robinson.)

What proportion of patients with chronic noncancer pain are prescribed an opioid medicine? Systematic review and meta‐regression of observational studies

“…In the USA following reports in 2017 that the prescription of opioids is now a contributor to reduced life expectancy in the USA and their life expectancy is lower than most high‐income countries , opioid mitigation strategies may have reduced opioid prescribing. A 2019 study noted a halving in the monthly incidence of initial opioid analgesics prescribed to opioid‐naïve enrolees of a USA health insurer from 1.63% of enrolees in July 2012 to 0.75% of enrolees in December 2017 . The differences across healthcare systems such as government regulations regarding access to opioids, reimbursements and views on the role opioids play in chronic noncancer pain management may contribute to the variation of opioid use across countries.…”

Commercial and public payer opioid analgesic prescribing policies: A case study

“…From 2015 to 2018, the number of prescriptions declined 30.5% for commercial payers, 11.4% for Medicaid, 15.2% for Medicare and 25.0% for cash (21). The number of opioid prescribers also declined during this time period from 55,180 to 53,850 similar to national analysis (22) even though opioid prescriptions and prescribers were added with the phased inclusion of Veteran's Administration prescription data into the PDMP (23). The Veteran Administration prescribers were using Michigan's PDMP by 2018 when prescribers and pharmacists were required to register (24).…”

“…However, the sheer number of policies and the right of patients to change payers or to pay cash complicates any such analysis. Investigators should also examine the decline in the number of prescribers, observed both in Michigan and nationally (22), and if that is related to the number of policies.…”

Treading the tightrope of opioid restrictions

“…The number of new prescriptions of opioids has undeniably decreased, but this trend pre-dates the CDC intervention. A study 4 published in March indicates that such prescriptions dropped by more than 50% between 2012 and 2017, with the decline clearly apparent long before December 2015, when the CDC draft guidelines were released. Meanwhile, deaths from opioid overdose have continued to climb steeply -a trend that can be attributed to the use of cheaper and more dangerous black-market opioids such as heroin and the ultra-potent fentanyl.…”